MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer
It is demonstrated that both MAPKAPK2 and HSP27 are necessary for TGFβ-mediated increases in MMP-2 and cell invasion in human prostate cancer.
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
The unexpected antitumor activity seen in mCRPC patients treated with the anti-PD-1 antibody pembrolizumab should lead to re-examination of PD-1 inhibition in prostate cancer.
Circulating giant macrophages as a potential biomarker of solid tumors
- D. Adams, Stuart S. Martin, M. Cristofanilli
- Biology, MedicineProceedings of the National Academy of Sciences
- 18 February 2014
Evidence is supplied that this circulating giant cell is a subset of disseminated tumor-associated macrophages capable of binding CTCs in peripheral blood of cancer patients, supporting the hypothesis that disseminated TAMs can be used as a biomarker of advanced disease and suggesting that they have a participatory role in tumor cell migration.
Soy Isoflavone Supplementation for Breast Cancer Risk Reduction: A Randomized Phase II Trial
A 6-month intervention of mixed soy isoflavones in healthy, high-risk adult Western women did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention and a possible adverse effect in premenopausal women.
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
- Hongjian Jin, Jonathan C Zhao, Irene M. Ogden, R. Bergan, Jindan Yu
- BiologyCancer Research
- 15 June 2013
These findings illustrate an AR-independent function of FoxA1 as a metastasis inhibitor and provide a mechanism by which recurrent FoxA 1 mutations contribute to prostate cancer progression.
Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells.
Genistein inhibits matrix metalloproteinase type 2 activity in six of seven prostate cell lines tested, blocks MMP-2 induction by TGF-beta, and inhibits cell invasion, and is seen at low nanomolar concentrations, corresponding to blood concentrations of free genistein attained after dietary consumption.
Inhibition of cancer cell invasion and metastasis by genistein
The variety of mechanisms by which genistein regulates individual steps of the metastatic cascade are discussed and the potential of this natural product as a promising therapeutic inhibitor of metastasis is highlighted.
Pharmacokinetics of thalidomide in an elderly prostate cancer population.
For both the single and multiple dosing of thalidomide, the apparent volume of distribution and half-life were significantly higher for the high- dose group than those for the low-dose group, and a dose-proportional increase in thalidmide steady-state concentrations was seen after multiple daily dosing.
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Pembrolizumab has activity in mCRPC when added to enzalutamide and Responses were deep and durable and did not require tumor PD-L1 expression or DNA-repair defects.
Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway
It is demonstrated that endoglin abrogates TGFβ-mediated cell motility, but does not alter cell surface binding of TGFα, while ALK2-Smad1 pathway activation is sufficient to restore a low-motility phenotype in endogli deficient cells.